Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 20/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5774627 | 0.94 | P2RX7 (0.52) | P2RX7 | |
| SCHEMBL5777988 | 0.87 | P2RX7 (0.68) | P2RX7 | |
| SCHEMBL5775727 | 0.83 | P2RX7 (0.64) | P2RX7 | |
| SCHEMBL7667288 | 0.82 | P2RX7 (0.76) | P2RX7 | |
| SCHEMBL4881659 | 0.80 | P2RX7 (0.67) | P2RX7 | |
| SCHEMBL5773616 | 0.78 | P2RX7 (0.53) | P2RX7 | |
| SCHEMBL5710431 | 0.77 | P2RX7 (0.62) | P2RX7 | |
| SCHEMBL5710397 | 0.77 | P2RX7 (0.62) | P2RX7 | |
| SCHEMBL7658517 | 0.76 | P2RX7 (0.77) | P2RX7 | |
| SCHEMBL5710435 | 0.76 | P2RX7 (0.60) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1292590-B1 | ADMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-01-18 | — | — | EP | claimed |
| US-6949539-B2 | Admantane derivatives | ASTRAZENECA AB (SE) | 2005-09-27 | — | — | US | claimed |
| US-20030187031-A1 | Antiinflammatory agents; autoimmune disease; rheumatic disorders | ASTRAZENECA AB (SE) | 2003-10-02 | — | — | US | claimed |
| EP-1292590-B1 | ADMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-01-18 | — | — | EP | disclosed |
| US-6949539-B2 | Admantane derivatives | ASTRAZENECA AB (SE) | 2005-09-27 | — | — | US | disclosed |
| US-20030187031-A1 | Antiinflammatory agents; autoimmune disease; rheumatic disorders | ASTRAZENECA AB (SE) | 2003-10-02 | — | — | US | disclosed |
| EP-1292590-A1 | ADMANTANE DERIVATIVES | AstraZeneca AB (SE) | 2003-03-19 | — | — | EP | disclosed |
| WO-2001094338-A1 | ADMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187031-A1 | Antiinflammatory agents; autoimmune disease; rheumatic disorders | IL1A, IL1R1, MTX1 | P2RX7 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.